2b5f10644f8fc336b6f73c10967edee119f8e8f3 gperez2 Mon Apr 1 17:42:56 2024 -0700 Code review edits, refs #33313 diff --git src/hg/htdocs/goldenPath/newsarch.html src/hg/htdocs/goldenPath/newsarch.html index bbf2309..a261c93 100755 --- src/hg/htdocs/goldenPath/newsarch.html +++ src/hg/htdocs/goldenPath/newsarch.html @@ -62,35 +62,33 @@

Mar. 26, 2024    New gnomAD v4 Constraint Metrics (hg38) and gnomAD Non-cancer filter (hg19/hg38)

We are pleased to announce the release of the gnomAD v4 constraint metrics for human assembly hg38/GRCh38 and the addition of a non-cancer filter for the GRCh37/hg19 Exome Variants v2.1.1 and the hg38/GRCh38 Genome Variants v3.1.1 tracks.

The gnomAD v4 constraint metrics tracks contain metrics of pathogenicity per-gene as predicted for -gnomAD v4.0 and identifies genes subject to strong selection against various classes of mutation. -These tracks contain metrics of pathogenicity per-gene as predicted for gnomAD v4.0 and -identifies genes subject to strong selection against various classes of mutation. The release of -the gnomAD v4 constraint metrics consists of two new subtracks in the gnomAD Constraint Metrics -composite track:

+gnomAD v4.0 and identify genes subject to strong selection against various classes of mutation. +The release of the gnomAD v4 constraint metrics consists of two new subtracks in the gnomAD +Constraint Metrics composite track:

  1. Transcript LoF Constraint track: Predicted constraint metrics at the whole transcript level for three different types of variation: missense, synonymous, and predicted loss of function.
  2. Transcript Missense Constraint track: The missense constraint tracks are built similarly to the LoF constraint tracks, however the items displayed are based on missense Z scores. All items are colored black, and individual Z scores can be seen on mouseover.

The GRCh37/hg19 Exome Variants v2.1.1 and the hg38/GRCh38 Genome Variants v3.1.1 tracks now have a non-cancer filter that allows the option to exclude/include variants from samples of individuals who were not ascertained for having cancer in a cancer study. These non-cancer subsets follow the new guidelines for clinical variant testing of BRCA1 and BRCA2 genes and are used for the assessment of breast cancer patients.